Ireland
--:--IST
Recruiting Not applicable

Hativ® ELectrocardiogram Monitoring on Patients With Suspected Arrhythmia

NCT06250712 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2024-02-22
Last updated
2026-10-05

Condition(s) studied

Arrhythmia

Investigational drug(s) / intervention(s)

Memo Patch continuous ECGHativ handheld ECG

Memo Patch continuous ECG: Continuous single-lead ECG monitoring for up to 7 consecutive days. Participants report the onset of symptoms using a mobile messaging chatbot or paper diary. For each reported symptomatic episode, a 20-minute ECG segment extending from 10 minutes before to 10 minutes after the reported onset is available for review.

Hativ handheld ECG: Handheld ECG monitoring using 10-second 6-lead recordings obtained at least twice daily and additionally whenever symptoms occur for 30 days. Recordings are transmitted through the companion smartphone application to a secure study server.

Study summary

HELP-A is a prospective, randomized, open-label, multicenter comparative-effectiveness trial comparing two ambulatory electrocardiographic monitoring strategies in adults with palpitations or dizziness and a nondiagnostic 12-lead ECG. A total of 588 participants are randomized 1:1 to 30-day intermittent handheld 6-lead ECG monitoring (Hativ) or up to 7 days of continuous single-lead patch ECG monitoring (Memo Patch). The primary endpoint is clinically informative symptom-rhythm correlation established with the initially assigned device by the 1-month follow-up visit. Participants without a symptom-rhythm correlation who remain symptomatic may undergo optional sequential monitoring with the alternative device after primary endpoint ascertainment. Clinical outcomes, arrhythmia-directed interventions, healthcare resource utilization, costs, and adverse events are assessed through 3 months.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 19 years or older. * Palpitations or dizziness not explained by the presenting 12-lead ECG. * A clinical indication for additional ambulatory ECG monitoring. * Ownership of and ability to use a compatible smartphone. * Ability to provide written informed consent and comply with study procedures Exclusion Criteria: * Physical disability or another condition that prevents appropriate use of the handheld ECG device. * Presence of a cardiac implantable electronic device or ventricular assist device. * Inability to read or understand the informed consent document. * Any other condition that, in the investigator's judgment, makes participation in the study inappropriate.

Primary outcome measure(s)

  • Clinically informative symptom-rhythm correlation with the initially assigned device by 1 month — From randomization through the 1-month follow-up visit
    Proportion of randomized participants with at least one participant-confirmed typical symptomatic episode documented with an interpretable ECG using the initially assigned device by the 1-month follow-up visit and before optional sequential monitoring. Primary-endpoint success comprises either a positive symptom-rhythm correlation or a negative-only symptom-rhythm correlation. A positive correlation is a qualifying symptomatic episode with an interpretable ECG showing a rhythm finding judged by central adjudication to be temporally and clinically concordant with that episode. A negative-only correlation requires at least one qualifying symptomatic episode with an interpretable ECG showing no concordant rhythm finding and no positive correlation by the 1-month visit.

Trial sites (4)

FacilityCityRegionStatus
Chonnam National University Hospital Gwangju Dong-gu Jaebongro 42 Recruiting
Wonju Severance Christian Hospital Wŏnju Gangwon-do Recruiting
Hallym University Dongtan Sacred Heart Hospital Gyeonggi-do Hwaseong-si Keunjaebong-gil 7 Recruiting
Korea University Anam Hospital Seoul Seongbuk-gu, 73 Goryeodae-ro Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06250712 on ClinicalTrials.gov ↗ ← All trials in South Korea